Home Introduction Divisions Organized Research Units Research Training Program Selected Scholarly Interests

Patricia W. Finn, MD. Department Chair

© Copyright 2014 The Board of Trustees of the University of Illinois

Andrei L. Gartel, Ph.D.

Academic Title: Associate Professor of Medicine and Molecular Genetics

Administrative Positions:

Division: Gastroenterology and Hepatology

Location: 840 S. Wood St., (MC 787), Chicago, IL 60612

Phone: (312)996-1855 (Office) Fax: (312)413-0342



PhD, Institute of Virology, Academy of Medical Sciences of the USSR (1983)

Postdoctoral Research Associate, University of Illinois at Chicago, Chicago, IL (1991-1993)

Faculty Positions:

Research Assistant Professor, Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL (1993-1994)

Research Assistant Professor, Department of Molecular Genetics, University of Illinois at Chicago, Chicago, IL (1994-2003)

Assistant Professor, Department of Medicine, University of Illinois at Chicago, Chicago, IL (2003-2009)

Associate Professor, Department of Medicine, University of Illinois at Chicago, Chicago, IL (2009-Present)

Clinical Specialties

Internal Medicine – Hepatology research

Research Interests

Positive and negative regulation of oncogenic transcription factor FoxM1.

Identification of novel anticancer drugs against human neoplasia.

Regulation and expression of the cyclin-dependent kinase inhibitor p21.

Selected Publications

Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F and Tyner AL. Myc represses the p21WAF1/CIP1 promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. USA. 98(8):4510-5, 2001.

Gartel AL and Tyner AL. The Role for the Cdk Inhibitor p21 in Apoptosis. Mol. Cancer Ther. 1: 639-649, 2002.

Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel AL and Hay N.  Activation of Akt/PKB abrogates G2/M cell cycle checkpoint following DNA damage. Mol. Cell Biol. 22(22):7831-7841, 2002.

Gartel AL and Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp. Cell Res. 283:17-21, 2003.

Gartel AL, Feliciano C and Tyner AL. A new method for determining the status of p53 in tumor cell lines of different origin.  Oncol. Res. 13:405-408, 2003.

Gartel AL, Radhakrishnan SK, Serfas MS, Kwon YH and Tyner AL. A novel p21WAF1/CIP1 transcript is highly dependent on p53 for its basal expression in mouse tissues. Oncogene. 23(49):8154-7, 2004.

Radhakrishnan SK and Gartel AL. The PPAR-gamma agonist pioglitazone post trancriptionally induces p21 in PC3 prostate cancer but not in other cell lines.  Cell Cycle. 4(4):582-4, 2005.

Nekhai S, Bhat UG, Ammosova T, Radhakrishnan SK, Jerebtsova M, Niu X, Foster A, Kayden TJ and Gartel AL. Novel transcriptional inhibitor ARC antagonizes HIV-1 and HCV. Oncogene. 26:3899-903, 2007.

Radhakrishnan SK, Bhat UG, Halasi M, and Gartel AL. P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents. Oncogene 27(9):1306-9, 2008.

Halasi M and Gartel AL. A novel mode of FoxM1 regulation: Positive auto-regulatory loop. Cell Cycle. 8(12):1966-7, 2009.

Gartel AL. A new target for proteasome inhibitors: FoxM1. Expert Opin. Investig. Drugs. 19(2):235-42, 2010.

Bhat U, Jagadeeswaran R, Halasi M and Gartel AL. Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells. J. Biol. Chem. 286(48):41425-33, 2011.

Wang M and Gartel AL. The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA. Oncotarget. 2(12):1218-26, 2011.

Halasi M and Gartel AL. Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA damage. PLoS One. 7(2):e31761, 2012.

Wang M, Halasi M, Kabirov K, Banerjee A, Landolfi J, Lyubimov AV and Gartel AL. Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis. Cell Cycle. 11(18):1-3, 2012.